Actinogen Doses First Patient in Phase 2b Alzheimer's Disease Trial; Shares Rally 16%
Actinogen Doses First Patient in Phase 2b Alzheimer's Disease Trial; Shares Rally 16%
Actinogen为2b期阿尔茨海默氏病试验的首位患者服药;股价上涨16%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册